Fueling the Future

of Immunotherapy

Rooted in our commitment to deliver comprehensive, unparalleled treatment for immune-excluded tumors, ImmunoGenesis is building complementary pipeline programs from the bottom up.

Our pipeline programs directly target several key pathology processes that make immune-excluded tumors so difficult to treat.

Our programs

Address the suppressive tumor microenvironment (TME)

Block immune checkpoint signals effectively

Prime an effective T-cell response

Pipeline

Pipeline programs, their indications, and their current stage of development.

CRC, colorectal cancer; GBM, glioblastoma multiforme; HPV, human papillomavirus; IND, investigational new drug; NPC, nasopharyngeal cancer; NSCLC, non–small cell lung cancer; PoC, proof of concept; STING, stimulator of interferon genes.

Clinical Programs

Our lead program, IMGS-001, is currently enrolling patients in a phase 1a/b clinical trial (NCT06014502). IMGS-001 is a cytotoxic immune checkpoint inhibitor (ICI) designed to destroy barriers blocking T cells, provide best-in-class PD-1 blockade, and activate T cells once they are at the tumor and ready to attack. Across preclinical models, IMGS-001 demonstrated differentiated efficacy where current drugs haven’t succeeded. IMGS-001 has the potential to become a superior foundation for add-on therapies.

Our second clinical program, IMGS-101 (evofosfamide), is a hypoxia-reversal agent and primer for enhanced checkpoint inhibition in immune-excluded tumor treatment. Immune T cells typically do not enter hypoxic zones. By reoxygenating the TME, IMGS-101 frees T cells to traffic to the tumor and attack cancerous cells.

Development Programs

IMGS-203 is a potent STING agonist with promising preclinical efficacy in difficult-to-treat tumor settings such as glioblastoma multiforme (GBM).

Stay tuned.

Our Vision

By harnessing cutting-edge science, the ImmunoGenesis pipeline is designed to redefine the immune-excluded tumor treatment landscape, re-envision existing immunotherapy treatment approaches, and ultimately, provide necessary treatments for the significant number of patients with these challenging tumors.

Learn more